Long-Term Use of Different Doses of Low-Molecular-Weight Heparin Versus Vitamin K Antagonists in the Treatment of Venous Thromboembolism

Annals of Vascular Surgery

Volumn 24, Issue 5, 2010, Pages 628-639

  Romera Villegas, A ^a   Cairols Castellote, M A ^a   Vila Coll, R ^a   Marti Mestre X ^a   Colome E ^b   Iguaz, I ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b Laboratorios LEO Pharma SA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANTICOAGULANT AGENT; ANTIVITAMIN K; BEMIPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; TINZAPARIN; WARFARIN; FIBRINOLYTIC AGENT; VITAMIN K GROUP;

ARTICLE; BIBLIOGRAPHIC DATABASE; BIOSIS; CANCER RECURRENCE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; DRUG WITHDRAWAL; EMBASE; HUMAN; LONG TERM CARE; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; RECANALIZATION; RECURRENCE RISK; RISK FACTOR; SYSTEMATIC REVIEW; VENOUS THROMBOEMBOLISM; ANTAGONISTS AND INHIBITORS; BLEEDING; BLOOD; CHEMICALLY INDUCED; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME;

ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; VITAMIN K;

EID: 77953476422     PISSN: 08905096     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.avsg.2009.08.006     Document Type: Article

References (25)

1. Pini M., Aiello S., Manotti C., et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 72 (1994) 191-197
2. Das S.K., Cohen A.T., Edmondson R.A., et al. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 20 (1996) 521-526
3. Gonzalez-Fajardo J.A., Arreba E., Castrodeza J., et al. Venographic comparison of subcutaneous low-molecular-weight heparin with oral anticoagulant therapy in the long-term treatment of deep venous thrombosis. J Vasc Surg 30 (1999) 283-290
4. Lopaciuk S., Bielska-Falda H., Noszczyk W., et al. Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis. Thromb Haemost 81 (1999) 26-31
5. Veiga F., Escriba A., Maluenda M.P., et al. Low-molecular weight heparin (enoxaparin) versus oral anticoagulant therapy (acenocoumarol) in the long-term treatment of deep venous thrombosis in the elderly: a randomized trial. Thromb Haemost 84 (2000) 559-564
6. Lopez-Beret P., Orgaz A., Fontcuberta J., et al. Low-molecular weight heparin versus oral anticoagulant in the long-term treatment of deep venous thrombosis. J Vasc Surg 33 (2001) 77-90
7. Hull R.D., Pineo G.F., and Brant R.F. for the LITE Trial Investigators. Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms. Am J Med 120 (2007) 72-82
8. Kakkar V.V., Gebska M., and Kadziola Z. Bemiparin Investigators. Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis. Thromb Haemost 89 (2003) 674-680
9. Hull R.D., Pineo G.F., Mah A.F., and Brant R.F. Long-term low molecular weight heparin treatment versus oral anticoagulant therapy for proximal deep vein thrombosis. Blood 96 (2000) 449a
10. Daskalopoulos M.E., Daskalopoulou S.S., Tzortzis E., et al. Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. Eur J Vasc Endovasc Surg 29 (2005) 638-650
11. Romera A., Cairols M.A., Vila-Coll R., et al. A randomised open-label trial comparing long-term subcutaneous low-molecular-weight heparin compared with oral anticoagulant therapy in the treatment of deep venous thrombosis. Eur J Vasc Endovasc Surg 37 (2009) 349-356
12. Beckman J.A., Dunn K., Sasahara A.A., and Goldhaber S.Z. Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. Thromb Haemost 89 (2003) 953-958
13. Kuchner N., Quiroz R., McKean S., Sasahara A.A., and Goldhaber S.Z. Extended enoxaparin monotherapy for acute symptomatic pulmonary embolism. Vasc Med 10 (2005) 251-256
14. Hamann H. Secondary prevention after deep venous thrombosis: low molecular weight heparin versus coumarin. Zentralbl Chir 124 (1999) 24-26
15. Lee A.Y., Levine M.N., Baker R.I., et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl. J Med 349 (2003) 146-153
16. Meyer G., Marjanovic Z., Valcke J., et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 162 (2002) 1729-1735
17. Deitcher S.R., Kessler C.M., and Merli G. for the ONCENOX Investigators. Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 12 (2006) 389-396
18. Hull R.D., Pineo G.F., and Brant R.F. for the LITE Trial Investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 119 (2006) 1062-1072
19. Iorio A., Guercini F., and Pini M. Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants. J Thromb Haemost 1 (2003) 1906-1913
20. van der Heijden J.F., Hutten B.A., Büller H.R., and Prins M.H. Vitamin K antagonists or low-molecular-weight heparin for the long term treatment of symptomatic venous thromboembolism. Cochrane Database Syst Rev. 1 (2002) CD002001
21. Ferretti G., Bria E., Giannarelli D., et al. Is recurrent venous thromboembolism after therapy reduced by low-molecular-weight heparin compared with oral anticoagulants?. Chest 130 (2006) 1808-1816
22. Akl E.A., Barba M., Rohilla S., et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2 (2008) CD006650
23. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analysis. B.M.J 327 (2003) 557-560
24. González-Fajardo J.A., Martín-Pedrosa M., Castrodeza J., Tamales S., and Vaquero-Puerta C. Effect of the anticoagulant therapy on the incidence of post-thrombotic syndrome and recurrent thromboembolism: comparative study of enoxaparin versus coumarin. J Vasc Surg 48 (2008) 953-959
25. Gómez-Outes A., Lecumberri R., Lafuente-Guijosa A., Martínez-González J., Carrasco P., and Rocha E. Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. J Thromb Haemost 2 (2004) 1581-1587